News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Sanofi and BI finalise swap to create market leading consume... Sanofi and BI finalise CHC and animal health swap
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Pharma looking to dual-action diabetes drugs to boost sales Pharma using FDA-mandated trials to give a commercial advantage.
News Diabetes drugs help Boehringer Ingelheim to grow Boehringer Ingelheim has posted a 4.1% rise in 2015 currency-adjusted sales, mainly thanks to a rapid acceleration in its diabetes drug revenues.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
